Safety and Efficacy of Split-Dose Thiopurine vs Low-Dose Thiopurine-Allopurinol Cotherapy in Pediatric Inflammatory Bowel Disease
暂无分享,去创建一个
L. Cococcioni | O. Borrelli | L. Pensabene | F. Kiparissi | E. Saliakellis | M. Puoti | Sara El-Kouly | Ms Sibongile Chadokufa | Ms Raechel Buckingham | Ms Edward Gaynor
[1] A. Griffiths,et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. , 2020, Journal of Crohn's & colitis.
[2] F. Hoentjen,et al. A comparative analysis of tioguanine versus low‐dose thiopurines combined with allopurinol in inflammatory bowel disease patients , 2020, Alimentary pharmacology & therapeutics.
[3] A. Griffiths,et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition , 2018, Journal of pediatric gastroenterology and nutrition.
[4] G. Peters,et al. High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients , 2018, Nucleosides, nucleotides & nucleic acids.
[5] S. Hanauer,et al. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study) , 2018, Alimentary pharmacology & therapeutics.
[6] A. Griffiths,et al. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.
[7] J. Duley,et al. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study , 2016, Inflammatory bowel diseases.
[8] J. Sanderson,et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic , 2013, International journal of clinical practice.
[9] J. Sanderson,et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. , 2012, Journal of Crohn's & colitis.
[10] S. Targan,et al. Split‐dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6‐MMP metabolism , 2012, Alimentary pharmacology & therapeutics.
[11] D. Shih,et al. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. , 2011, World journal of gastroenterology.
[12] Mary C. Henthorn,et al. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. , 2010, Journal of Crohn's & colitis.
[13] C. Lees,et al. Tolerability and safety of mercaptopurine in azathioprine‐intolerant patients with inflammatory bowel disease , 2007, Alimentary pharmacology & therapeutics.
[14] P. Söderkvist,et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease , 2006, Gut.
[15] S. Hanauer,et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.
[16] S. Targan,et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.
[17] R. Weinshilboum,et al. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.